Product Pipeline

EyePoint has developed five FDA-approved products utilizing our proprietary DurasertTM and VerisomeTM Technologies.

We are utilizing our Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions, and are available to collaborate on our VerisomeTM Technology.

Dexycu (dexamethasone intraocular suspension) 9%Approved
Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mgApproved
Yutiq shorter duration treatmentPreclinical
Durasert TKI
Potential Indication: Wet AMD
Collaboration on glaucomaPreclinical
Verisome Technology - PGE
Potential Indication: glaucoma
Verisome Technology - NSAID
Potential Indication: cataract surgery inflammation
Dexycu (dexamethasone injectable suspension) 9%
Learn More at dexycu.com
click here for full Prescribing Information

Please complete the form below to receive information on the availability of Dexycu.

Dexycu (dexamethasone injectable suspension) 9%
Learn More at yutiq.com
click here for full Prescribing Information

YUTIQ Physician Perspective

Click here to see additional YUTIQ videos

Yutiq® Shorter Duration for Posterior Uveitis

Potential Indication: posterior segment uveitis

EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.

DurasertTM Bioerodible TKI

Potential Indication: Wet AMD

EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs.